Navigation Links
Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
Date:5/26/2010

SAN DIEGO, May 26 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

This is the second patent granted of a large estate filed by Amira Pharmaceuticals that describe novel small molecule inhibitors of the DP2 (CRTH2) receptor.  Amira has successfully completed Phase 1 studies on two DP2 receptor antagonists, AM211 and AM461, and anticipates these compounds will be developed for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other allergic conditions.

"This UK patent for AM461 is another significant milestone for the Amira DP2 program and clearly shows that Amira can effectively develop patent-protected, novel drug candidates," said John Hutchinson, Ph.D., Vice President of Chemistry.

Bob Baltera, Chief Executive Officer of Amira, added, "This patent demonstrates Amira's continued focus on developing robust programs with strong patent protection, rather than single drug candidates.  We plan to use the same strategy in our continued development of our research programs, including our LPA program."

The newly granted claims cover novel phenoxyphenyl acetic acid compounds, their formulation and uses in Prostaglandin D2 (PGD2)-dependent conditions.  The patent also describes the method of synthesis of this class of DP2 antagonists and their routes of administration for the treatment of DP2 receptor-mediated diseases and conditions.

About Amira

F
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
3. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
4. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone ... to relapse compared to placebo in patients with ... study published this week in the ... . Results of the study ... Drug Application (NDA) filing for three-month paliperidone palmitate ...
(Date:3/27/2015)... , March 27, 2015 BioCorRx, Inc. ( ... Santa Ana, California is a healthcare solutions organization, ... is estimated at $22 billion in the U.S. alone. The ... of FDA-approved Naltrexone in a specially compounded form for outpatient ... Australia and New Zealand ) ...
(Date:3/27/2015)... N.C. , March 27, 2015 Across ... essential to meeting challenges in clinical development, market education, ... tighter regulations, the Medical Affairs function is expected to ... mature markets. According to research by ... participants have a group dedicated to Medical Affairs. Among ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Cephalon, Inc. (Nasdaq: CEPH ) announced ... BioAssets Development Corporation (BDC), following receipt of interim data ... administration of a tumor necrosis factor (TNF) inhibitor for ... a neuropathic inflammatory pain condition that occurs when the ...
... Harold Kaefer has been named Rhythmlink,s new director of ... medical device, diagnostic and laser industries, Mr. Kaefer will ... department. "Harold Kaefer has joined Rhythmlink as ... the company,s engineering team and direct its new product ...
Cached Medicine Technology:Cephalon Exercises its Option to Acquire BioAssets Development Corporation 2Cephalon Exercises its Option to Acquire BioAssets Development Corporation 3Cephalon Exercises its Option to Acquire BioAssets Development Corporation 4Rhythmlink International Announces Change in Engineering Management 2
(Date:3/29/2015)... IN (PRWEB) March 29, 2015 The culmination ... world is coming when the Final Four invades ... basketball tournament has been one filled with excitement, buzzer-beaters, and ... have been busted, superstars have been made, and future professional ... just be down to the four teams that advanced through ...
(Date:3/29/2015)... 2015 The Claudia Cohen Research ... announce today that Dr. Beth Y. Karlan has ... Cohen Research Foundation Prize for Outstanding Gynecologic Researcher. The ... Gynecologic Oncology 46th Annual Meeting on Women's Cancer in ... Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer ...
(Date:3/29/2015)... New York, NY (PRWEB) March 29, 2015 ... operators that conduct clinical trials and research, manage ... products to help their clients reach regulation standards. ... the pharmaceutical and medical device manufacturing sectors. Industry ... services, from early- to late-stage clinical research for ...
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) pending in the ... scheduled the litigation’s next Case Management Conference for ... that the meeting will address the progress of ... who allegedly experienced heart attacks, strokes and other ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
... Anderson Cancer Center suggest that the use of an anti ... tumor growth in the// human pancreas and also resulted in ... National Cancer Institute issued on Dec.20 reported that a combination ... effective than just the administration of chemotherapy agent gemcitabine. ...
... stress-relief by just holding her husband’s hand, says a study. ... that the institution of marriage// is losing ground. ... the University of Virginia, finds that women in a threatening ... hand and this has been observed in brain scans. ...
... cards from active members of the,British Lung Foundation, warning ... to Chronic Obstructive Pulmonary Disease (COPD) patients in Scotland. ... be set, to ensure patients received the best quality ... Disease is a term that refers to a number ...
... Testosterones can slow down the progression of Alzheimer's disease ... the primary male sex hormone, is one// in a ... , The findings, published in the December ... insight into the relationship between testosterone loss and AD, ...
... and keeping active to stay fit, old people especially those ... agile, if they just indulge// in brain exercises, to enhance ... in age, researchers said. ,Previous insights have indicated ... mind games. The study led by Sherry Willis, a human-development ...
... possible by Colonoscopy. More patients are willing to undergo this ... bud at the very onset. ,Cary Gross, ... University, found that there is a significant rise in colonoscopy ... in people .This has helped early treatment possible. ...
Cached Medicine News:Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2Health News:Colonoscopy Aids Early Detection of Colon Cancer 2
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
10" overall length, 5" handle....
...
Medicine Products: